Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Myers

Physician Assistant, Medical Roanoke, VA Physician Assistant

NPI 1962737213 CMS profile 11161051

3501 Colonial Green Circle, Roanoke, VA 24018

Open in the dashboard

General payments

$13,752

687 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Myers of Roanoke, VA is reported in the CMS Open Payments database as having received $13,752 across 687 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,383 122
2024 General $2,279 136
2023 General $2,837 164
2022 General $2,181 134
2021 General $2,072 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Myers
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Erin Myers were reported at $4,383. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Erin Myers Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,072 $156 $41–$563 $132
2022 $2,181 $185 $55–$649 $149
2023 $2,837 $199 $58–$717 $160
2024 $2,279 $206 $62–$740 $164
2025 $4,383 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $2,247 30 payments
  2. Novo Nordisk Inc $1,253 76 payments
  3. Lilly USA, LLC $1,080 81 payments
  4. Abbott Laboratories $875 62 payments
  5. Dexcom, Inc. $867 52 payments
  6. Amgen Inc. $799 48 payments
  7. Xeris Pharmaceuticals, Inc. $672 37 payments
  8. Tandem Diabetes Care, Inc. $534 24 payments
  9. Radius Health, Inc. $472 17 payments
  10. Mannkind Corporation $423 25 payments
  11. Other $4,530 235 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,051 681 payments
  2. Travel and Lodging $1,701 6 payments
Products named General payments · program years 2021–2025
  1. Omnipod $2,247 30 payments
  2. Ozempic $875 57 payments
  3. RYBELSUS $828 54 payments
  4. Dexcom G6 Transmitter $662 42 payments
  5. JARDIANCE $544 43 payments
  6. MOUNJARO $434 30 payments
  7. AFREZZA $423 25 payments
  8. Tymlos $414 13 payments
  9. Tirosint $403 18 payments
  10. t:slim X2 Insulin Pump with Control-IQ $402 22 payments
  11. Other $9,127 519 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

3,076

Median for Physician Assistant: 241

Drug cost

$1,116,098

Median for Physician Assistant: $4,110

Branded share of claims

50.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 146 $198,966
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 72 $96,077
Mounjaro Tirzepatide Brand 67 $80,938
Tresiba Flextouch U-200 Insulin Degludec Brand 42 $71,352
Tresiba Flextouch U-100 Insulin Degludec Brand 99 $71,220
Xultophy 100-3.6 Insulin Degludec/Liraglutide Brand 42 $61,876
Synjardy Xr Empagliflozin/Metformin Hcl Brand 52 $58,510
Jardiance Empagliflozin Brand 39 $56,283
Trulicity Dulaglutide Brand 35 $44,733
Farxiga Dapagliflozin Propanediol Brand 35 $39,107

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$141,268

Medicare's payments for the services billed

Medicare patients

426

Average age 73

Services billed

7,509

291 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 66%
Arthritis 45%
Chronic kidney disease 29%
Osteoporosis 28%
Ischemic heart disease 25%
Depression 19%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$199 39 —
RECORLEV
$148 — —
AFREZZA
$142 — —
RYBELSUS
$124 27 —
Ozempic
$124 146 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

687 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record